Investment Rating - The report maintains an "Outperform" rating for JD Health [6][18]. Core Insights - JD Health achieved a revenue of 35.3 billion yuan in H1 2025, representing a year-on-year increase of 25%. The growth was driven by an increase in active user numbers and the online penetration of health products [10][18]. - The company reported a non-IFRS net profit margin increase from 9.3% to 10.1% year-on-year, with operating profit margin rising from 3.6% to 6.2% [2][11]. - Active users surpassed 200 million, with a 10% year-on-year growth, and daily consultation orders exceeded 500,000 [3][12]. Revenue Summary - In H1 2025, product revenue reached 29.3 billion yuan, up 23% year-on-year, while service revenue was 6 billion yuan, reflecting a 34% increase [10][18]. - The number of merchants increased to over 150,000, up more than 50,000 from the end of the previous year [10][18]. Profitability Summary - The gross profit margin for H1 2025 was 25.2%, an increase of 1.6 percentage points year-on-year, attributed to growth in advertising revenue and improved supply chain capabilities [2][11]. - Fulfillment expenses rose from 2.9 billion yuan to 3.6 billion yuan, but the fulfillment cost rate decreased from 10.4% to 10.1% due to cost dilution from increased order volume [2][11]. Operational Data Summary - The company is actively promoting instant retail services, connecting over 200,000 pharmacies, and expanding online medical insurance payment services to nearly 200 million people [3][12]. - JD Health has launched AI medical products, with over 50 million users served by AI medical assistants by the end of June [3][12]. Financial Forecast - Revenue projections for 2025-2027 are 70.1 billion, 80.8 billion, and 90.9 billion yuan, with adjustments of +7%, +10%, and +11% respectively [18]. - Adjusted net profit estimates for the same period are 5.5 billion, 6.2 billion, and 6.9 billion yuan, with adjustments of +25%, +27%, and +28% [18].

Investment Rating - The report assigns a neutral rating to the company with a target price of HKD 70.40, indicating a potential downside of 9.4% from the current closing price of HKD 77.75 [6][11]. Core Insights - The company has experienced significant growth in innovative drug sales, with a year-on-year revenue increase of 16% in 1H25, driven by a 23% increase in innovative drug sales, which now account for 55% of product sales revenue [6][12]. - The management plans to increase R&D investment while keeping the total R&D expenditure as a percentage of total revenue below 30% [6]. - The company has achieved several business development (BD) milestones, including the approval of six innovative drugs in 1H25 and expectations to launch 47 new products and indications from 2025 to 2027 [6][12]. Summary by Sections Financial Performance - In 1H25, the company reported a revenue of approximately RMB 20 billion from collaboration income, up from RMB 14 billion in 1H24 [6]. - The gross margin improved by 0.4 percentage points to 86.6%, with a notable decrease in selling, general, and administrative (SG&A) expenses and R&D expense ratios [6][12]. - The projected revenue for 2025 is RMB 32,543 million, with a net profit forecast of RMB 7,698 million [12]. Business Development - The company has successfully completed three overseas agreements in 2025, including a deal with GSK valued at approximately USD 12 billion [6]. - The management's targets for the employee stock ownership plan include achieving over 25% annual growth in innovative drug sales and submitting 5-8 new drug applications each year from 2025 to 2027 [6]. Valuation - The report raises the revenue forecast for 2025-2027 by about 2% and the net profit forecast by 7-8% to reflect the contributions from various BD transactions and expected improvements in profit margins [6][12]. - The DCF valuation model indicates a fair value of HKD 70.40 per share, with no premium or discount applied to the Hong Kong shares compared to A-shares [6][7].

Investment Rating - The report maintains a "Buy" rating for the company, anticipating a price increase of over 15% in the next 6-12 months [4][11]. Core Insights - The company announced the establishment of an AI-driven international supply chain technology platform, marking the official launch of its globalization strategy. The platform aims to provide comprehensive solutions for small and micro enterprises in the global supply chain, including flexible supply chain services, financial support, currency management, and digital empowerment [2]. - The company has formed partnerships with over 30 international financial institutions and several leading regional and industry players, actively expanding its business in Southeast Asia. Notable collaborations include providing cross-border supply chain services for Carro, assisting Chinese merchants on Shopee, and partnering with Shein's core suppliers to explore markets in Vietnam and Morocco [3]. - The platform will incorporate blockchain technology and promote the tokenization of real-world assets (RWA), transforming high-quality international supply chain assets into standardized, traceable digital assets on the blockchain, thereby enhancing capital turnover efficiency in the global supply chain [3]. - The company is expected to see continued growth in its e-commerce, AI, and robotics sectors, which will drive the expansion of its supply chain technology platform. The increasing proportion of high-value-added revenue is anticipated to optimize the overall fee structure and improve profitability [4]. Financial Projections - The company forecasts revenue growth from RMB 1,068 million in 2023 to RMB 2,180 million by 2027, with a compound annual growth rate (CAGR) of approximately 28% [9]. - The projected net profit attributable to the parent company is expected to rise from RMB 268 million in 2023 to RMB 1,014 million by 2027, reflecting a CAGR of 44% [9]. - The expected dividend payout for 2025 is approximately RMB 950 million, resulting in a projected dividend yield of 8.3% [4].

Investment Rating - The report maintains a "Buy" rating for the company [5][12]. Core Views - The company's Q2 revenue accelerated significantly, driven by high-frequency food delivery, which boosted both the main site and logistics business. However, losses from the food delivery segment were greater than expected, negatively impacting overall profits. The pace of improvement in food delivery losses may be ahead of schedule [3][9]. - The company is expected to achieve revenues of 1,327.6 billion, 1,396.7 billion, and 1,464.2 billion yuan for 2025-2027, with adjusted net profits of 22.8 billion, 43.6 billion, and 52.0 billion yuan respectively. The target market capitalization is set at 542.1 billion yuan, corresponding to a target share price of 186.37 HKD [3][12]. Summary by Sections Financial Performance - In Q2, the company achieved a total revenue of 282.4 billion yuan, with the electric category contributing 178.9 billion yuan (up 23.4% year-on-year) and daily necessities contributing 103.4 billion yuan (up 16.4% year-on-year). The logistics segment generated revenue of 51.6 billion yuan, reflecting a year-on-year increase of 16.6% [9][10]. - The adjusted net profit for Q2 was 7.39 billion yuan, down 48.9% year-on-year, primarily due to increased losses in the food delivery segment [9][10]. Profitability Forecast - The report projects a significant decline in adjusted net profit for 2025 to 16.35 billion yuan, followed by a recovery to 37.20 billion yuan in 2026 and 45.56 billion yuan in 2027. The adjusted net profit margin is expected to improve gradually over the forecast period [10][12]. Valuation - The company is assigned an 8X PE valuation for its retail and new business segments for 2026, leading to a target market capitalization of 542.1 billion yuan. The target share price is set at 186.37 HKD, based on the current exchange rate [3][12][15].

Investment Rating - The report maintains an "Outperform" rating for Ascentage Pharma with a target price of HKD 90.70, reflecting a potential upside from the current price of HKD 90.20 [2][24]. Core Insights - Ascentage Pharma reported strong product sales growth, with revenue from product sales reaching RMB 213 million, a 70.5% increase year-on-year, driven by a 93% increase in sales of Olverembatinib [3][15][17]. - The company achieved a gross profit of RMB 212 million with a gross margin of 90.7%, indicating improved operational efficiency [3][15]. - R&D expenses increased by 19% year-on-year to RMB 529 million, reflecting ongoing global clinical trials and the company's commitment to advancing its pipeline [3][18]. Financial Performance - For the first half of 2025, total revenue was RMB 234 million, down 71.6% year-on-year, primarily due to a one-off intellectual property income from Takeda in the previous year [3][15]. - The company recorded a net loss of RMB 591 million during the same period, with cash reserves totaling approximately RMB 3.15 billion [3][15][18]. - The report projects revenues for FY25, FY26, and FY27 to be RMB 730 million, RMB 3.16 billion, and RMB 3.02 billion, respectively, with corresponding net profits of RMB -1.09 billion, RMB 1.39 billion, and RMB 990 million [9][21]. R&D Progress - The approval of Lisaftoclax® for treating CLL/SLL patients was a significant milestone, and the initiation of the GLORA-4 Phase III trial for higher-risk MDS patients is expected to accelerate the drug's market entry [4][16][20]. - Efficacy data presented at the 2025 ASCO meeting showed promising results for Lisaftoclax® in MDS and CMML patients, with an overall response rate of 80% in newly diagnosed patients [20][21]. Market Dynamics - The report highlights the significant unmet medical need in the MDS treatment landscape, particularly for higher-risk patients, where current therapies have limited efficacy [19][20]. - The combination of National Reimbursement Drug List coverage and expanded hospital access has driven sales growth for Olverembatinib, with a 114% increase in sales volume [17][18].

Investment Rating - The report maintains a "Strong Buy" rating for the company, expecting it to outperform the benchmark index by over 20% in the next six months [7][22]. Core Insights - The company reported a revenue of 19.652 billion yuan for the first half of 2025, representing a year-on-year increase of 4.2%. The net profit attributable to shareholders was 1.646 billion yuan, showing a significant year-on-year growth of 52.56%. The gross margin for the period was approximately 19.8%, up by 2.6 percentage points year-on-year [1][3]. Financial Performance Summary - **Revenue Forecasts**: The projected total revenue for the company is expected to grow from 38.294 billion yuan in 2024 to 53.957 billion yuan by 2027, with year-on-year growth rates of 20.3%, 14.0%, 10.6%, and 11.8% respectively [3][8]. - **Net Profit Forecasts**: The net profit attributable to shareholders is forecasted to increase from 2.699 billion yuan in 2024 to 4.912 billion yuan in 2027, with growth rates of 145.5%, 28.2%, 21.4%, and 17.0% respectively [3][8]. - **Earnings Per Share (EPS)**: The EPS is projected to rise from 2.47 yuan in 2024 to 4.49 yuan in 2027 [3][8]. - **Valuation Ratios**: The price-to-earnings (P/E) ratio is expected to decrease from 29.3 in 2024 to 16.1 in 2027, while the price-to-book (P/B) ratio is projected to decline from 3.2 to 2.1 over the same period [3][8]. Business Drivers - The company's growth is driven by improvements in the smartphone product structure and growth in the automotive sector. The smartphone-related products have maintained the highest global market share, with significant revenue growth in hybrid lenses and large-format modules [7][8]. - The automotive business is experiencing rapid growth due to the accelerated penetration of Advanced Driver Assistance Systems (ADAS), with the company securing significant contracts in the laser radar segment [7][8]. - The report highlights the potential for growth in the AIoT sector, particularly in smart glasses, where the company continues to lead in market share [7][8]. Investment Recommendation - The report suggests that the ongoing high-endization of smartphone cameras and the expansion of intelligent driving will create new growth opportunities for the optical industry. The company is well-positioned to benefit from these industry trends, with a target price set at 103.3 HKD based on a 30x P/E ratio for 2025 [7][8].

Investment Rating - The report assigns a positive investment rating, suggesting subscription to the IPO based on the anticipated demand and market conditions [10]. Core Insights - Jaxin International (3858.HK) is a tungsten mining company focused on the Bakuta tungsten mine in Kazakhstan, which is one of the largest tungsten resources globally [1][3]. - The company plans to dual-list on the Hong Kong Stock Exchange and the Astana International Exchange [1]. - The Bakuta project is expected to commence commercial production in April 2025, with a target mining and processing capacity of 3.3 million tons of tungsten ore in 2025, and an anticipated increase to 4.95 million tons per year by Q1 2027 [1]. Company Overview - Jaxin International is primarily engaged in the development of the Bakuta tungsten mine, which is noted for its significant tungsten oxide (WO3) resources [1]. - The company has established sales agreements for white tungsten concentrate with Jiangxi Copper and Jiangxi Tungsten for 2025 and 2026 [1]. Financial Performance - The company is projected to have no revenue before 2025, with an expected revenue of HKD 126 million by June 2025 [2]. - The net losses for the years 2022, 2023, and 2024 are reported at HKD 93.661 million, HKD 78.92 million, and HKD 172.97 million respectively, with a reduced loss of HKD 5.996 million by June 2025 [2]. Industry Status and Outlook - China is the largest tungsten resource country, holding over 50% of global reserves, but its tungsten production has decreased from 69,000 tons in 2019 to 67,000 tons in 2024 [3]. - The demand for tungsten is increasing in various sectors, with consumption rising from 47,300 tons in 2019 to 55,300 tons in 2024, and projected to reach 65,500 tons by 2029 [3]. Advantages and Opportunities - The Bakuta tungsten mine is strategically located and benefits from the Belt and Road Initiative, enhancing its market potential [4]. - The company has a strong management team with valuable industry experience, which supports its growth and expansion [4]. Use of Proceeds - Approximately 55% of the net proceeds (HKD 598.3 million) will be allocated to the development of the Bakuta project, with 10% for ammonium paratungstate (APT) capacity development, and 25% for repaying bank loans [6]. IPO Details - The IPO is set to launch on August 28, 2025, with an issue price of HKD 10.92 and a total fundraising amount of HKD 1.199 billion [8]. - The post-IPO market capitalization is estimated at HKD 47.96 billion [8].

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of HKD 25.49 [2][9]. Core Views - The company's 1H25 performance showed a revenue decline of 1.7% year-on-year to HKD 50.267 billion, and a net profit attributable to shareholders decreased by 15.9% to HKD 7.872 billion, which was below expectations [6]. - The renewable energy segment's core profit increased by 1.5% year-on-year to HKD 5.637 billion, indicating growth potential despite challenges in the thermal power sector [6][8]. - The company aims to add 10GW of new renewable energy capacity in 2025, with 4.8GW already connected to the grid in 1H25 [6][9]. Financial Performance Summary - Revenue projections for the upcoming years are as follows: - 2024: HKD 105.284 billion - 2025E: HKD 102.846 billion - 2026E: HKD 110.355 billion - 2027E: HKD 112.074 billion [5]. - Net profit attributable to shareholders is forecasted as: - 2024: HKD 14.388 billion - 2025E: HKD 12.507 billion - 2026E: HKD 13.430 billion - 2027E: HKD 13.818 billion [5]. - The company’s EPS (Earnings Per Share) for 2025E is projected at HKD 2.42, with a PE ratio of 7.66 [5]. Operational Insights - The core profit from the thermal power business decreased by 2.7% to HKD 2.641 billion in 1H25, while the pure thermal power business (excluding coal) saw a core profit increase of 20.6% to HKD 2.788 billion [7]. - The average utilization hours for wind power increased by 3.7% to 1268 hours, outperforming the national average [8]. - The company’s coal power generation price (excluding tax) decreased by 2.55 cents per kWh to HKD 0.3912 per kWh, while the unit fuel cost dropped by 3.52 cents per kWh to HKD 0.2413 per kWh [7]. Valuation Metrics - The target market capitalization is set at HKD 131.97 billion, reflecting a 25% discount to account for the potential impact of the renewable energy spin-off [9]. - The company’s PB (Price to Book) ratio for 2025E is estimated at 0.82, while the PE ratio is projected at 17.4x [9].

Investment Rating - The investment rating for the company is "Buy" with a target price not specified [5]. Core Views - The company has demonstrated strong performance with a significant increase in revenue and profit, attributed to rising aluminum product prices and sales volume [1][2]. - The company has optimized its cost structure, leading to improved margins and profitability, particularly in its aluminum and alumina segments [2][3]. - A substantial share buyback program has been initiated, reflecting the company's confidence in its future growth prospects [4]. Financial Performance - For the first half of 2025, the company achieved revenue of 81.039 billion yuan, a year-on-year increase of 10.1%, and a net profit of 12.361 billion yuan, up 35% [1]. - The aluminum alloy segment contributed revenue and gross profit of 51.88 billion yuan and 13.09 billion yuan, respectively, with sales volume increasing by 2.4% [2]. - The alumina segment saw revenue and gross profit of 20.65 billion yuan and 5.95 billion yuan, respectively, with sales volume up 15.6% [2]. Cost Management - The company has effectively controlled costs, with a notable decrease in sales and administrative expenses, and a significant reduction in financial expenses by 17.7% [3]. - The gross margin for aluminum products has improved due to a combination of rising prices and effective cost management strategies [2][3]. Shareholder Returns - The company reported a basic earnings per share of 1.31 yuan, a 36% increase year-on-year, and has adjusted its dividend distribution strategy, opting not to declare an interim dividend [4]. - A share buyback of approximately 2.6 billion Hong Kong dollars was executed, with plans for further buybacks of at least 3 billion Hong Kong dollars, indicating strong confidence in future performance [4].

Investment Rating - The report maintains a "Recommended" rating for the company with a target price of 30.4 HKD [2][8]. Core Insights - The company reported a significant revenue increase of 31.7% in H1 2025, achieving 482 million CNY, and a net profit growth of 76.0%, reaching 121 million CNY [2][8]. - The company is experiencing strong growth in both its neurointervention and peripheral intervention segments, with revenues of 304 million CNY (+25.0%) and 176 million CNY (+46.2%) respectively in H1 2025 [8]. - The company has a robust product pipeline with 73 products or candidates, of which 50 are already commercialized in China, and several new products are expected to be approved in the near future [8]. - The overseas market is identified as a new growth driver, with H1 2025 overseas revenue reaching 16 million CNY (+36.9%), and the company has 22 products commercialized in 27 countries [8]. Financial Summary - The company is projected to achieve total revenue of 1,044 million CNY in 2025, with a year-on-year growth rate of 33.5% [4]. - The net profit for 2025 is estimated at 195 million CNY, reflecting a substantial growth of 95.0% compared to the previous year [4]. - The earnings per share (EPS) are forecasted to be 0.59 CNY for 2025, with a corresponding price-to-earnings (P/E) ratio of 36.4 [4][8].